Atrium Therapeutics, Inc. Common Stock (RNA NASDAQ) stock market data APIs
$8.8613
0.72(8.1%)
as of September 18, 2026
Try our APIs with
free plan!
Atrium Therapeutics, Inc. Common Stock Financial Data Overview
Price chart is built with
Anychart
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. It has a research collaboration and license agreement with Bristol-Myers Squibb Company and Eli Lilly and Company. The company was incorporated in 2025 and is headquartered in San Diego, California.
Prev. Close
8.8613
Open
9.5789
High
9.5865
Low
8.5947
52 wk Range
8.66-16.77
Market Cap
153 M
Shares Outstanding
17 106 K
Revenue
35 837 K
EPS
-1.18
Beta
0.93
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Atrium Therapeutics, Inc. Common Stock (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Atrium Therapeutics, Inc. Common Stock data using free add-ons & libraries
Get Atrium Therapeutics, Inc. Common Stock Fundamental Data
Atrium Therapeutics, Inc. Common Stock Fundamental data includes:
- Net Revenue: 35 837 K
- EBITDA: -68 528 000
- Earnings Per Share: -5
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Atrium Therapeutics, Inc. Common Stock Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2026-08-13
- EPS/Forecast: -0.64
Get Atrium Therapeutics, Inc. Common Stock End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Atrium Therapeutics, Inc. Common Stock News
New
Wall Street Money Is Leaving Just As Atrium’s (RNA) Pipeline Turns Real
On August 13, Atrium Therapeutics (NASDAQ:RNA) reported second-quarter 2026 results that mixed real clinical progress with a familiar biotech question: how long the cash lasts. The company disclosed F...
Atrium Therapeutics to Participate in Upcoming Investor Conferences
SAN DIEGO, Sept. 2, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, tod...
Can Atrium Therapeutics (RNA)’s $15 Million Milestone From Bristol-Myers Squibb (BMY) Validate its RNA Platform?
On August 13, two pharmaceutical companies tied to the same cardiovascular research deal delivered major updates. Atrium Therapeutics, Inc. (NASDAQ:RNA) earned a $15 million milestone payment from Bri...
Atrium Therapeutics Reports Second Quarter 2026 Financial Results
-- IND clearance for ATR 1072 and launch of Corventis Phase 1/2 trial in PRKAG2 syndrome -- -- Achieved second milestone payment under global cardiovascular collaboration with Bristol Myers Squibb --...
Get Atrium Therapeutics, Inc. Common Stock fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
